BioCentury
ARTICLE | Company News

Immuno-Designed Molecules in deal with Medarex

October 23, 2000 7:00 AM UTC

Immuno-Designed Molecules (Paris, France) acquired worldwide rights to use MEDX's MDX-210 bispecific anti-HER-2/neu antibody in connection with cell therapy, plus certain rights to MDX-220 and MDX-447...